Webinar – Pain R&D: Plenty of Pain to Go Around, But Who’s Making Gains?
Despite a growing need for safe, effective pain drugs, the drug development pipeline is sparsely populated. Recent setbacks like those facing Lilly and Pfizer’s anti-NGF drug have chilled the atmosphere for new lines of research. In an Endpoints webinar on August 11th, Lei Lei Wu of Endpoints will sit down with Jan Adams of Grünenthal to discuss the situation and how to improve access to patients.
